The company noted it reduced the list price of Symbicort at the start of this year. The change comes amid increasing attention and criticism about the cost of inhalers. The four major ...
A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper ... with a fast action, in a single inhaler. A Viatris spokesperson said: "Viatris obviously ...
Viatris (formerly Mylan) has become the first drugmaker to win full FDA approval for a generic version of AstraZeneca's top-selling respiratory drug Symbicort ... reduce the cost of treatment ...